Latest annual · FY2021
Millions- Total revenues
- 351
- Operating income
- (181)
- Net income
- (158)
Latest quarter · Q3 FY2026
Millions- Operating income
- (34)
- Net income
- (32)
Daily close · AVIRIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions4.21 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
Atea Pharmaceuticals, Inc. (AVIR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$180.9 million | -$193 million | 10-K 2026-03-05 · proof | |
| Net income | -$158.3 million | -$168.4 million | 10-K 2026-03-05 · proof | |
| Cash from operating activities | -$132 million | -$135.5 million | 10-K 2026-03-05 · proof | |
| Total assets | $315.2 million | $464.7 million | -32.2% | 10-K 2026-03-05 · proof |
| Total liabilities | $39.8 million | $25.8 million | +54.2% | 10-K 2026-03-05 · proof |
| Cash and cash equivalents | $95.7 million | $64.7 million | +47.9% | 10-K 2026-03-05 · proof |
- What was Atea Pharmaceuticals, Inc. (AVIR)'s operating income in fiscal 2025?
- Atea Pharmaceuticals, Inc. (AVIR) reported operating income of -$180.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$193 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Atea Pharmaceuticals, Inc. (AVIR)'s net income in fiscal 2025?
- Atea Pharmaceuticals, Inc. (AVIR) reported net income of -$158.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$168.4 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What was Atea Pharmaceuticals, Inc. (AVIR)'s cash from operating activities in fiscal 2025?
- Atea Pharmaceuticals, Inc. (AVIR) reported cash from operating activities of -$132 million for fiscal 2025 (the year ended Dec 31, 2025), against -$135.5 million the year before. Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Atea Pharmaceuticals, Inc. (AVIR)'s total assets?
- As of Dec 31, 2025, Atea Pharmaceuticals, Inc. (AVIR) reported total assets of $315.2 million, against $464.7 million a year earlier (-32.2%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Atea Pharmaceuticals, Inc. (AVIR)'s total liabilities?
- As of Dec 31, 2025, Atea Pharmaceuticals, Inc. (AVIR) reported total liabilities of $39.8 million, against $25.8 million a year earlier (+54.2%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
- What are Atea Pharmaceuticals, Inc. (AVIR)'s cash and cash equivalents?
- As of Dec 31, 2025, Atea Pharmaceuticals, Inc. (AVIR) reported cash and cash equivalents of $95.7 million, against $64.7 million a year earlier (+47.9%). Source: the 10-K filed with the SEC on Mar 5, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:AVIR&period_type=annual&limit=5"Information only, not investment advice.